[BEP-chemotherapy in patients with testicular tumors--is it worthwhile?].
Since 1985 44 consecutive patients with testicular cancer have been treated with a modified BEP regimen. 70% had metastatic disease and 30% received adjuvant therapy. After mean follow-up of 26 (8-56) months, 91% of patients are alive and all are in remission. Chemotherapy-related side effects were alopecia (100%), myelosuppression (100%), nausea/vomiting (89%) and fever (66%). Patients reported nausea has been rare. It is concluded that BEP chemotherapy is a highly effective treatment which secures complete remission or cure even in patients with advanced metastatic disease. In retrospect the patients considered the treatment worthwhile despite the stress involved.
Hess
U
U
Medizinische Klinik C, Kantonsspital St. Gallen.
Jungi
W F
WF
Morant
R
R
Schmid
L
L
Senn
H J
HJ
Bandhauer
K
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin
BEP-Chemotherapie bei Patienten mit Hodentumoren--Hat es sich gelohnt?